Conference Reports for NATAP

11th IAS Conference on HIV Science 18-21 July 2021 Back

Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084       IAS: Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - (07/21/21)   IAS: WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)   IAS: CAB + RPV Failure Risk Factor in 10% of Large French Cohort - (07/21/21)   IAS: Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)   IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)   IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)   IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)   Long-Acting Preferences & Acceptability   IAS: Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)   IAS: US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - (07/23/21)   IAS: High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)   IAS: Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)   Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) - (07/09/21)   full IAS coverage by NATAP: 11th IAS Conference on HIV Science 18-21 July 2021   IAS: Metabolics, Comorbidities & Aging at IAS 2021 - (08/16/21)   IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)   Injectable PrEP for Men & Women - HPTN 083, 084   IAS: Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)   IAS: HPTN083 Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)   IAS: Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)   IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)